Table 3

Relative decreases in HAM-D scores for subgroups of patients with a major depressive episode after 6 weeks of treatment with WS® 5570 or placebo (full analysis set, last observation carried forward)

Subgroup based on baseline score

Mean % decrease ± SD, number of patients

p-value


WS® 5570 600 mg/day N = 119

WS® 5570 1200 mg/day N = 124

Placebo N = 81

WS® 5570 600 mg/day vs placebo

WS® 5570 1200 mg/day vs placebo


Baseline HAM-D total score cutoff 20 (split at 25th percentile)

<20

54.2 ± 26.3, 25

56.0 ± 29.9, 31

32.7 ± 40.5, 14

0.09

0.07

≥ 20

51.1 ± 28.3, 94

46.4 ± 32.5, 93

24.4 ± 33.6, 67

<0.001

<0.001

Baseline HAM-D total score cutoff 23 (split at median)

<23

55.5 ± 28.1, 56

53.1 ± 29.7, 64

26.8 ± 38.8, 37

<0.001

<0.001

≥ 23

48.4 ± 27.4, 63

44.2 ± 33.9, 60

25.1 ± 31.4, 44

<0.001

<0.01

Baseline HAM-D total score cutoff 25 (split at 75th percentile)

<25

53.6 ± 27.3, 83

52.8 ± 30.2, 85

28.6 ± 37.7, 49

<0.001

<0.001

≥ 25

47.4 ± 28.9, 36

40.2 ± 34.5, 39

21.7 ± 29.8, 32

<0.001

0.02

Baseline CGI item 1, severity of illness

<5*

51.2 ± 28.7, 67

49.9 ± 31.5, 62

28.0 ± 36.1, 46

<0.001

<0.01

≥ 5§

52.4 ± 26.9, 52

47.7 ± 32.7, 62

23.1 ± 33.3, 35

<0.001

<0.001


* "Moderately ill or less severe"

§ "Markedly ill or more severe"

Kasper et al. BMC Medicine 2006 4:14   doi:10.1186/1741-7015-4-14

Open Data